Axsome Therapeutics Wins US FDA Review for Narcolepsy Drug Application
() -- Axsome Therapeutics (AXSM) said Wednesday the US Food and Drug Administration accepted its new drug application for AXS-12 to treat cataplexy, or muscle weakness, in narcolepsy. A target review date of May 1, 2027, has been set, and the FDA indicated it currently does not expect to convene an advisory committee m